FIELD: medicine.
SUBSTANCE: disclosed medicinal agent contains glucosidase inhibitors of general formula (IIa).
EFFECT: higher clinical effectiveness of mucoviscidosis treatment ensured by repairing the membrane addressing of protein delF508 and its activity as an ionic carrier without cytotoxic effect.
6 cl, 7 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROBIOTIC STRAINS FOR TREATMENT AND/OR PREVENTION OF DIARRHEA | 2013 |
|
RU2642320C2 |
| USE OF CFTR MODULATORS FOR TREATING CEREBROVASCULAR CONDITIONS | 2019 |
|
RU2820288C2 |
| THYMOSIN ALPHA-1 FOR USE IN TREATING CYSTIC FIBROSIS | 2016 |
|
RU2724932C2 |
| METHOD FOR PRE-IMPLANTATION GENETIC TESTING OF CYSTIC FIBROSIS | 2021 |
|
RU2777078C1 |
| PHARMACEUTICAL COMBINATION FOR TREATMENT AND/OR CHEMOSENSITISATION OF TUMOURS RESISTANT TO ANTICANCER DRUGS | 2007 |
|
RU2396974C2 |
| SOLID FORMS OF N-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL-)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUIINOLINE-3-CARBOXAMIDE | 2009 |
|
RU2518479C2 |
| RECOMBINANT ADEN-ASSOCIATED VIRUS, WHICH IS HYBRID OF AAV9 AND AAVrh74 SEROTYPES, WITH REDUCED TROPISM FOR LIVER TISSUE | 2019 |
|
RU2812279C2 |
| METHOD FOR DETECTION OF TUMOUR GROWTH Pdcd4 SUPPRESSOR SUPPRESSION INHIBITORS IN TUMOUR CELLS AND pLucPdcd4 GENETIC CONSTRUCT FOR ITS IMPLEMENTATION | 2016 |
|
RU2640909C1 |
| METHOD OF PRENATAL AND POSTNATAL DNA-DIAGNOSTICS OF DOWN, EDWARDS PATAU SYNDROME MUTATION delF508 IN GENE OF MUCOVISCIDOSIS AND RHESUS-FACTOR OF FOETUS | 2014 |
|
RU2539778C1 |
| SOLID FORMS OF 3-(2, 2-DIFLUOROBENZO[D][1,3] DIOXOL-5-YL)CYCLOPROPANCARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | 2011 |
|
RU2579370C2 |
